AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03408210 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow and lymphoid irradiation
Description: Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12 Gy TMLI (fraction size of 4 Gy given once a day on days -6, -5 and -4).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0.
Study NCT02504931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: A Randomized Controlled Trial Design will randomize subjects to one of two arms. Sertraline is the active medication treatment arm.
Study NCT02504931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
Study NCT00054028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin
Description: Given IV
Study NCT00054028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00054028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01742689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin intranasal spray
Description: 10 microgram per puff, 40 microgram is Descript
Study NCT01742689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intranasal spray
Description: Saline spray identical to desmopressin, administered as 4 sprays
Study NCT00791518 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: No intervention
Study NCT01742689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository
Description: Indomethacin suppository 100 milligram single dose
Study NCT01742689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin suppository
Description: Indomethacin suppository 100 milligram single dose
Study NCT01867138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Study NCT01867138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study NCT01867138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Study NCT01867138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Study NCT02231385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetic Acid
Description: Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time.
Study NCT02964585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin
Description: 100 mg
Study NCT02964585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily for 16 weeks
Study NCT02591368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligament reconstruction tendon interposition
Description: In this procedure the trapezium is removed and one of the patient's own tendons (or portion of the tendon), usually the flexor carpi radialis or abductor pollicis longus, is passed through a drill hole in the thumb metacarpal and is used to suspend the first metacarpal base.
Study NCT02591368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suspensionplasty with one-suture construct
Description: In this procedure the trapezium is removed and an Arthrex mini tightrope system using Fiberwire suture is drilled across the first metacarpal to the second metacarpal and is used to suspend the first metacarpal base instead of a tendon.
Study NCT02591368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suspensionplasty with two-suture construct
Description: In this procedure the trapezium is removed and two Arthrex mini tightrope systems using Fiberwire sutures are drilled across the first metacarpal to the second metacarpal and are used to suspend the first metacarpal base instead of a tendon.
Study NCT01761500 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Modified BFM-90 protocol
Description: Using Modified BFM-90 protocol to treat Chinese children and Adolescents with NHL
Study NCT01416623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: henatinib
Description: Henatinib Maleate Tablets
Study NCT01595594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Doxycycline and Sham aPDT
Description: It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days
Study NCT01595594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aPDT + Doxycycline Placebo
Description: The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
Study NCT01754792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pinitol
Description: Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
Study NCT03999086 — intervention group
Intervention type: PROCEDURE
Intervention: Intervention
Description: We will utilize thromboelastography to discern when to transfuse blood products in the setting of multi-level spinal fusion
Study NCT03999086 — intervention group
Intervention type: OTHER
Intervention: Control Group
Description: Laboratory analysis to guide transfusion
Study NCT03861156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0316
Description: Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
Study NCT01994993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin and metronidazole and gentamicin
Description: IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Study NCT01994993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin and gentamicin and clindamycin
Description: IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Study NCT01994993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gentamicin and Piperacillin- tazobactam
Description: IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Study NCT01994993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care antibiotics and metronidazole
Description: IV infusion of standard of care antibiotics and metronidazole for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Study NCT01994993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole, clindamycin, or piperacillin-tazobactam
Description: IV infusion of metronidazole, clindamycin, or piperacillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Study NCT00499746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol
Description: oral dose, once per day
Study NCT00499746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral dose, once per day
Study NCT00499746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: oral dose, once per day
Study NCT00499746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: oral dose, once per day
Study NCT02273960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986004 75 mg IV
Description: BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes
Study NCT02273960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986004 225 mg IV
Description: BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes
Study NCT02273960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986004 675 mg IV
Description: BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes
Study NCT02273960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986004 1500 mg IV
Description: BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes
Study NCT03514901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental combination beyond Focal Progression
Description: Vemurafenib is taken on a 28-day cycle. Each dose consists of four 240 mg (960 mg) tablets twice daily for 28 consecutive days. The first dose should be taken in the morning and the second dose in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Vemurafenib tablets should be swallowed whole with a glass of water and should not be chewed or crushed.~Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken orally, once daily for 21 consecutive days, followed by a 7-day break. Each subsequent treatment cycle should start after the 7-day treatment break has elapsed. The dose should be taken in the morning.~Local treatment (i.e. surgery, radiotherapy).
Study NCT03514901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab or Nivolumab
Description: Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes every 3 weeks OR Nivolumab 3 mg/kg is administered intravenously over 60 minutes every 2 weeks.
Study NCT01070108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
Study NCT01070108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
Study NCT01070108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
Study NCT02009631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib (ABT-888)
Study NCT02009631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01050257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir IV
Description: Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.
Study NCT01050257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir Oral
Description: Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.
Study NCT05023746 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetron lung cancer panel
Description: Follows the principle of synchronous blinding. The enrolled cases are coded, and the enrolled samples are detected with Genetron lung cancer panel and comparison methods. The detection results are compared, and the samples that are inconsistent with the detection results of similar products on the market are reviewed by the the Sanger sequencing method, when the site detection results compared with Sanger sequencing method are inconsistent, Sanger's detection results are recognized. The results were determined independently according to the cutoff values or interpretation requirements provided by each method, and relevant statistics were used to evaluate clinical application performance of Genetron lung cancer panel.
Study NCT00584558 — intervention group
Intervention type: PROCEDURE
Intervention: Catheter Ablation
Description: Catheter Ablation of arrhythmias
Study NCT03560050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition assistance
Description: Participating family child care home providers in and around the Oklahoma City (OKC) area will be randomized to either the Nutrition (n=26), or an environmental health comparison group (n=26). Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
Study NCT03560050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children's environmental health
Description: Participating family child care home providers in and around the OKC area will be randomized to either the Nutrition (n=26), or an environmental health intervention (n=26) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Intervention will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
Study NCT01764568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Description: The metacognitive group training program that will form the basis of the 16 session MCT intervention has been described in previous research (Moritz \& Woodward 2007a; Moritz \& Woodward 2007b; Moritz 2011) and can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of two 8-module cycles occurring twice a week for 8 weeks, for a total of 16 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects. Subjects will be able to attend the alternate (Cognitive Remediation) group after completion of the MCT group if they wish.
Study NCT01764568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Description: The CR group will use a computerized cognitive remediation program that has been used with schizophrenia patients, Scientific Brain Training Pro (SBT Pro; Vianin et al, 2010). Modules focus on attention, working memory, verbal memory, and planning and reasoning. Each session will incorporate psycho-educational group discussion of strategies, and individual work through exercises on personal tablet computers and personalized level of difficulty. The CR treatment will take place twice per week for 8 weeks, for a total of 16 sessions. Groups will consist of 4-10 subjects. Subjects will be able to attend MCT after completion of CR if they wish.
Study NCT03960294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOZE Sleep App
Description: DOZE is an evidence-based cognitive behavioural therapy for insomnia app created specifically for use with adolescents and young adults.
Study NCT03206190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPRS Score and clinical signs
Description: Patients will clinically characterized by using the SPRS Score and the inventory V3
Study NCT03206190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognition Testing using CANTAB
Description: Patients will be tested using the CANTAB
Study NCT02477553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DA - Quantitative
Study NCT02477553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DA - Verbal
Study NCT01017445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boonme stick exercise
Description: individual exercise daily
Study NCT04253457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1ml of triamcinolone (40mg/1ml)
Description: Single injection of 1ml of triamcinolone (40mg/1ml)
Study NCT04253457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1ml of triamcinolone (40mg/1ml)
Description: Single injection of 1ml of triamcinolone (40mg/1ml)
Study NCT03770104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ETT insertion depth using Spanish recommendations
Description: Infants included in this assignment group will be intubated using the formula 5.5 plus weight, when requiring oral intubation in the delivery room.
Study NCT03770104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ETT insertion depth using international recommendations
Description: Infants included in this assignment group will be intubated using the formula 6 plus weight, when requiring oral intubation in the delivery room.
Study NCT02472236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: 200µg,injected subcutaneously,once a week.
Study NCT02472236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.5mg,oral,two times.
Study NCT00952614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluocinolone acetonide (Retisert Implant, Bausch and Lomb)
Description: sustained release device consisting of 0.59 mg of fluocinolone acetonide
Study NCT04231916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal imaging device
Study NCT02364440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultherapy™ System
Description: Subjects will receive 20 lines Ultherapy™ System Treatment over their right and left hand with 1.5 and 3.0 probe respectively
Study NCT03380767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trauma-induced coagulopathy treatment
Description: Transfusion as needed according to the assay methodology
Study NCT03464149 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: One armed study, blood from each patient is analysed by four assays ( two 3rd generation and two 2nd generation assays)
Description: Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)
Study NCT03358940 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: urine collection
Description: For patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection the day of the inclusion. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
Study NCT03302286 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Heart-lung machine primining solution which includes Mannitol
Description: This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
Study NCT03302286 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Heart-lung machine primining solution which does not include Mannitol
Description: This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
Study NCT05777239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant Approach for Crestal Sinus Elevation
Description: Crestal Sinus Elevation by elevating the sinus membrane with a blunt ended dental implant approach
Study NCT03921333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose response efficacy of plant extracts
Description: 300mg
Study NCT03921333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Middle dose response efficacy of plant extracts
Description: 500mg
Study NCT03921333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Dose response efficacy of plant extracts
Description: 700mg
Study NCT03921333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose microcrystalline